COPD
News from the FDA/CDC
FDA rejects mepolizumab on efficacy, but supports safety for COPD
Pulmonary-Allergy Drugs Advisory Committee fails to recommend approval for add-on mepolizumab use by COPD patients.
From the Journals
Ten tips for managing patients with both heart failure and COPD
Diagnose them early, treat them early, and build a team of experts and support services with the patients.
From the Journals
Medicare’s bundled pay plan didn’t deliver big cost savings
Conference Coverage
Noninvasive ventilation during exercise benefited a subgroup of COPD patients
SAN DIEGO –
Conference Coverage
Lung volume reduction procedures on the rise since 2011
NETT trial results showed the benefits of lung volume–reduction surgery for COPD.
Conference Coverage
Aclidinium bromide for COPD: No impact on MACE
Cardiovascular risk was studied in COPD patients treated with aclidinium bromide.
From the Journals
Education sessions upped COPD patients’ knowledge of their disease
With the right education tool, patients can gain knowledge about their disease.
Conference Coverage
AZD8871 delivered significant bronchodilation in two-week study
AZD8871 at once daily doses of 100 mcg and 600 mcg elicited statistically significant, clinically relevant, and dose-ordered differences in trough...
Conference Coverage
COPD patient subset gains no benefit from low-dose theophylline
For people with COPD at high risk of exacerbation, the addition of low-dose theophylline to inhaled corticosteroids conferred no overall clinical...
Conference Coverage
Most COPD patients on triple therapy can withdraw steroids
SAN DIEGO – It’s safe to withdraw inhaled corticosteroids in many COPD patients on long-term triple therapy and up to one exacerbation in the...